DE602004009083T2 - Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie - Google Patents

Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie Download PDF

Info

Publication number
DE602004009083T2
DE602004009083T2 DE602004009083T DE602004009083T DE602004009083T2 DE 602004009083 T2 DE602004009083 T2 DE 602004009083T2 DE 602004009083 T DE602004009083 T DE 602004009083T DE 602004009083 T DE602004009083 T DE 602004009083T DE 602004009083 T2 DE602004009083 T2 DE 602004009083T2
Authority
DE
Germany
Prior art keywords
rosuvastatin
oatp
statin
human
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004009083T
Other languages
German (de)
English (en)
Other versions
DE602004009083D1 (de
Inventor
Helen Jean Macclesfield AMBROSE
Ruth Macclesfield MARCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602004009083D1 publication Critical patent/DE602004009083D1/de
Application granted granted Critical
Publication of DE602004009083T2 publication Critical patent/DE602004009083T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Semiconductor Lasers (AREA)
DE602004009083T 2003-07-26 2004-07-26 Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie Expired - Lifetime DE602004009083T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0317592 2003-07-26
GBGB0317592.4A GB0317592D0 (en) 2003-07-26 2003-07-26 Method
PCT/GB2004/003236 WO2005012566A2 (en) 2003-07-26 2004-07-26 Use of polymorphisis in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy

Publications (2)

Publication Number Publication Date
DE602004009083D1 DE602004009083D1 (de) 2007-10-31
DE602004009083T2 true DE602004009083T2 (de) 2008-06-19

Family

ID=27772801

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004009083T Expired - Lifetime DE602004009083T2 (de) 2003-07-26 2004-07-26 Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie

Country Status (12)

Country Link
US (1) US7700277B2 (https=)
EP (1) EP1651774B1 (https=)
JP (1) JP4166257B2 (https=)
AT (1) ATE373730T1 (https=)
CY (1) CY1107801T1 (https=)
DE (1) DE602004009083T2 (https=)
DK (1) DK1651774T3 (https=)
ES (1) ES2291899T3 (https=)
GB (1) GB0317592D0 (https=)
PL (1) PL1651774T3 (https=)
PT (1) PT1651774E (https=)
WO (1) WO2005012566A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269188A1 (en) * 2004-07-21 2008-10-30 Inserm Oatp-C Gene C463a Polymorphism Underlies Variable Response to Statin Therapy
JP2011512813A (ja) * 2008-02-29 2011-04-28 アイシス イノベーション リミテッド 診断法
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
US8765377B2 (en) 2011-10-13 2014-07-01 Boston Heart Diagnostics Corporation Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
CA2968221A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
US10572811B2 (en) 2015-01-29 2020-02-25 Splunk Inc. Methods and systems for determining probabilities of occurrence for events and determining anomalous events
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN110904215A (zh) * 2019-12-16 2020-03-24 西安和合医学检验所有限公司 用于同步检测slco1b1基因的两个snp位点的基因多态性的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) * 1861-04-09 Coffee-pot
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) * 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8902689D0 (en) 1989-02-07 1989-03-30 Ici Plc Assay method
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
JP4071277B2 (ja) 1993-11-12 2008-04-02 ピーエイチアールアイ・プロパティーズ・インコーポレーテッド 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット
EP1141282A2 (en) 1998-08-07 2001-10-10 Axys Pharmaceuticals, Inc. Human anion transporter genes atnov
US20020090622A1 (en) * 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds

Also Published As

Publication number Publication date
EP1651774A2 (en) 2006-05-03
DE602004009083D1 (de) 2007-10-31
US20070031838A1 (en) 2007-02-08
DK1651774T3 (da) 2008-01-07
US7700277B2 (en) 2010-04-20
WO2005012566A2 (en) 2005-02-10
ATE373730T1 (de) 2007-10-15
CY1107801T1 (el) 2013-06-19
JP4166257B2 (ja) 2008-10-15
EP1651774B1 (en) 2007-09-19
PT1651774E (pt) 2007-11-16
WO2005012566A3 (en) 2005-06-16
PL1651774T3 (pl) 2007-12-31
GB0317592D0 (en) 2003-08-27
ES2291899T3 (es) 2008-03-01
JP2007500005A (ja) 2007-01-11

Similar Documents

Publication Publication Date Title
Langdahl et al. Osteoporotic fractures are associated with an 86‐base pair repeat polymorphism in the interleukin‐1‐receptor antagonist gene but not with polymorphisms in the interleukin‐1β gene
Vance et al. Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17
Lappalainen et al. Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations
Litt et al. A gene for episodic ataxia/myokymia maps to chromosome 12p13
Keen et al. Evidence of association and linkage disequilibrium between a novel polymorphism in the transforming growth factor β 1 gene and hip bone mineral density: a study of female twins
US20080214662A1 (en) Methods for the treatment of dementia based on apo e genotype
Meisel et al. Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease
CN101356286A (zh) 心血管病症的诊断和疗法
Nozaki et al. Homozygosity mapping to chromosome 5p15 of a gene responsible for Hartnup disorder
DE60026150T2 (de) Diagnostika und therapeutika für osteoporose
DE602004009083T2 (de) Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie
DE60115349T2 (de) Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)
Hattori et al. Association of neurotrophin-3 gene variant with severe forms of schizophrenia
Alrasadi et al. Functional mutations of the ABCA1 gene in subjects of French–Canadian descent with HDL deficiency
Schrauwen et al. Genetic variants in the RELN gene are associated with otosclerosis in multiple European populations
Persico et al. Enhanced APOE2 transmission rates in families with autistic probands
DE60036750T2 (de) Verfahren zur Abschätzung der Sensitivität für Osteoporose-Medikamente
Malkin et al. Strong association between polymorphisms in ANKH locus and skeletal size traits
DE602005004026T2 (de) Einen transkriptionsfaktor kodierendes humanes prädispositionsgen für autismus sowie dessen verwendungen
Fallin et al. No association between the very low density lipoprotein receptor gene and late‐onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population‐based and clinic samples
De Jonghe et al. A novel type of hereditary motor and sensory neuropathy characterized by a mild phenotype
Rigoli et al. Apolipoprotein AI-CIII-AIV genetic polymorphisms and coronary heart disease in type 2 diabetes mellitus
Jurado et al. Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures
Taylor et al. Association of endothelial nitric oxide synthase genotypes with bone mineral density, bone loss, hip structure, and risk of fracture in older women: the SOF study
Ermakov et al. Variation in femoral length is associated with polymorphisms in RUNX2 gene

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: MARCH, RUTH, MACCLESFIELD, CHESHIRE, GB

Inventor name: AMBROSE, HELEN, JEAN, MACCLESFIELD, CHESHIRE, GB

8364 No opposition during term of opposition